Neuropace Inc.
Mountain View, CA
- UEI
- VV9XSUEG8QD3
- CAGE
- 4QQR1
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 455 N Bernardo Ave, Mountain View, CA 94043, USA
- Website
- neuropace.com
- Founded
- 1999
- Employees
- 51-250
- Estimated annual revenue
- $10M-$50M
- Industry
-
- Health Care
- Health Care Equipment & Services
- Health Care Providers & Services
- SIC code
- 38 Instruments & Related Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $303,181 |
| FY2025 | $470,813 |
| FY2024 | $187,025 |
| FY2023 | $234,002 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Veterans Affairs | $168,900 | |
| 2 | Department of Health and Human Services | $134,281 |
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Neurostimulator | Veterans Integrated Service Network 6 (VHA) | $36,310 | |
| Surgical implant | Veterans Integrated Service Network 16 (VHA) | $47,970 | |
| Neuropace, INC.:1336391 [26-001427] | NIH Clinical Center | $115,286 | |
| Prosthetics neurostimulator implant | Veterans Integrated Service Network 22 (VHA) | $37,600 | |
| Surgical implant | Veterans Integrated Service Network 16 (VHA) | $47,020 |
Latest 5 listed here. See the rest on GovTribe.
Grant awards
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| The Trustees Of The University Of Pennsylvania | R61NS125568 | $137,638 | |
| The Trustees Of The University Of Pennsylvania | R61NS125568 | $161,927 | |
| The Trustees Of The University Of Pennsylvania | R61NS125568 | $168,183 |
Similar vendors
About the company
Neuropace Inc., a Mountain View, California-based for-profit medical device manufacturer, sells implantable neurostimulation systems, surgical implants, electrodes, and related accessories to federal health agencies as a prime contractor (95% of awards), competing exclusively through full and open competition with no set-aside designations. The company manufactures electromedical and electrotherapeutic apparatus (26 awards) and surgical appliances and supplies (23 awards) under PSC Medical and Surgical Instruments, Equipment, and Supplies, with primary focus on the RNS System for treating focal onset seizures and severe epilepsy disorders.
Neuropace's customer base concentrates heavily with the Department of Veterans Affairs across multiple Veterans Integrated Service Networks. The top five agencies account for 86% of awards by count and 93% by combined potential value. Veterans Integrated Service Network 22 leads with 23 awards valued at $725 thousand combined potential; VISN 17 follows with 15 awards worth $657 thousand; NIH Clinical Center holds 7 awards valued at $274 thousand; VISN 20 accounts for 5 awards at $228 thousand; and VISN 5 carries 3 awards worth $102 thousand. This concentration reflects Neuropace's role as the primary federal supplier of responsive neurostimulation devices to VA medical centers nationwide. Representative recent prime contracts include a $115,286 purchase order from NIH Clinical Center (December 2025) for neurostimulation devices and accessories supporting clinical operations; a $47,970 firm fixed-price purchase order from VISN 17 (March 2026) for surgical implants; and a $60,325 purchase order from NIH Clinical Center (September 2025) for electrodes and accessories supporting scheduled neurosurgeries.
Award volume has grown markedly—from 6 awards in 2022 to 15 in 2025—with only 2 awards issued year-to-date through the snapshot date. Three awards carrying $141 thousand in combined potential value face ultimate completion within the next twenty-four months, presenting modest recompete exposure. Neuropace acts as a sub-recipient on federal research grants, contributing data engineering, software development, and ECoG (electroencephalography) analysis support to University of Pennsylvania-led NIH-funded research on seizure biomarker discovery in epilepsy. Across three grant sub-awards dated March 2024, September 2024, and July 2025, Neuropace software engineers extract RNS System patient data from its Patient Data Management System and deploy automated data-sharing pipelines to support multi-center research teams at University of Pennsylvania, New York University, and University of California San Francisco, while Neuropace scientists perform spectral analysis and develop electrographic seizure classifier models. The company's federal footprint reflects sustained demand for specialized implantable neurostimulation hardware across VA networks and NIH research facilities, with minimal subcontractor engagement and no participation in government-wide IDIQs, GWACs, or BPAs.
Quick answers
Is Neuropace Inc. registered in SAM.gov?
Yes. Neuropace Inc.'s SAM.gov registration is active through March 24, 2027.
How much has Neuropace Inc. received in federal contracts?
Federal contracts obligated $470,813 to Neuropace Inc. in fiscal year 2025 and $1,195,021 in fiscal years 2023 through 2027.
How does Neuropace Inc. rank among federal contractors?
Neuropace Inc. ranked #85 in NAICS 334510 in FY2025.
What is Neuropace Inc.'s most recent federal award?
Neuropace Inc.'s most recent federal contract award is Neurostimulator (36C24626P0485), from Veterans Integrated Service Network 6 (VHA), on March 11, 2026.
On GovTribe
See Neuropace Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors